Modality
siRNA
MOA
FXIai
Target
PRMT5
Pathway
RAS/MAPK
DLBCLMCC
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
Jan 2020
→ Aug 2027
Phase 2Current
NCT08253101
1,990 pts·MCC
2020-01→2027-03·Active
NCT05608297
2,142 pts·DLBCL
2023-06→2027-08·Completed
4,132 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-2412mo awayPh2 Data· MCC
2027-08-231.4y awayPh2 Data· DLBCL
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Active
P2
Complet…
Catalysts
Ph2 Data
2027-03-24 · 12mo away
MCC
Ph2 Data
2027-08-23 · 1.4y away
DLBCL
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08253101 | Phase 2 | MCC | Active | 1990 | ORR |
| NCT05608297 | Phase 2 | DLBCL | Completed | 2142 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 |